camphor + menthol + sumatriptan

**Camphor + menthol + sumatriptan** is a combination migraine product marketed as **MIGRANOW** and developed by **PureTek**. It combines oral **sumatriptan succinate** tablets with a topical analgesic gel containing **camphor 4%** and **menthol 10%**. The principal established pharmacologic component is sumatriptan, a small-molecule selective agonist of serotonin **5-HT1B** and **5-HT1D** receptors that is used for acute abortive treatment of migraine by promoting cranial vasoconstriction and inhibiting trigeminal nociceptive signaling. The camphor and menthol gel provides topical counterirritant analgesia through sensory nerve stimulation, including activity at thermosensitive TRP channels. Based on the provided context, the product has been positioned for acute symptomatic treatment of migraine, and possibly cluster headache in some promotional materials, but it is noted that the labeling has not been FDA-approved and the product has not been found by FDA to be safe and effective.

Brand names

MIGRANOW

Other names

camphor + menthol + sumatriptanCamphotrex Extra Strength Pain Relieving Gel + sumatriptan